Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib Combined with Inotuzumab Ozogamicin for Ph+ ALL with Persistent MRD
NCT05603156Phase 2Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olverembatinib in acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Minimal Residual Disease Clearance Rate. Status: unknown.
02
Drugs
olverembatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05603156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603156.